Evidence map›Paper›PMID 35512793›Full record

ArticleRespirology (Carlton, Vic.)2022

Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis.

Cathryn T Lee, Mary E Strek, Ayodeji Adegunsoye, Alyson W Wong, Deborah Assayag, Gerard Cox, Charlene D Fell, Jolene H Fisher, Andrea S Gershon, Andrew J Halayko and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Respirology (Carlton, Vic.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Epigenome-Wide Analysis Identifies Pollution-Sensitive Loci in Fibrotic Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025
    Article
  7. The Role of Particle Inhalation in Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Interstitial Lung Disease and Sarcoidosis.Clinics in chest medicine · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. The Long-Term Respiratory Perils of War.American journal of respiratory and critical care medicine · 2022
    Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 2 countries.

Cathryn T LeePulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois, USA.ORCID 0000-0002-0963-7505
Mary E StrekPulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois, USA.ORCID 0000-0002-7671-1023
Ayodeji AdegunsoyePulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois, USA.ORCID 0000-0002-7015-9610
Alyson W WongDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Deborah AssayagDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Gerard CoxMedicine (Respirology), McMaster University, Hamilton, Ontario, Canada.
Charlene D FellDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.
Jolene H FisherDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-8123-923X
Andrea S GershonDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-0246-594X
Andrew J HalaykoPhysiology/Internal Medicine (Respirology), University of Manitoba, Winnipeg, Manitoba, Canada.
Nathan HamblyMedicine (Respirology), McMaster University, Hamilton, Ontario, Canada.
Nasreen KhalilDivision of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Martin KolbMedicine (Respirology), McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0003-3837-1467
Stacey D LokDepartment of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Hélène ManganasDépartement de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Veronica MarcouxDepartment of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Julie MorissetDépartement de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Mohsen SadatsafaviFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
Shane ShaperaDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.
Teresa ToResearch Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
Pearce WilcoxDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Christopher J RyersonDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-1049-393X
Kerri A JohannsonDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-1205-5511
University of British Columbia · CAMcMaster University · CAUniversity of Chicago · USUniversity of Toronto · CACentre Hospitalier de l’Université de Montréal · CAUniversity of Calgary · CAUniversity of Saskatchewan · CAHospital for Sick Children · CAMcGill University · CAUniversity of Manitoba · CA

Funding

RESEARCH TRAINING IN RESPIRATORY BIOLOGYT32HL007605 · NHLBI · UNIVERSITY OF CHICAGO · PI Yun Fang, Gokhan M. Mutlu · 1985 to 2026
$18.1M
Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810k
NHLBI NIH HHS K23 HL146942NHLBI NIH HHS T32 HL007605NIEHS NIH HHS P30 ES027792
6 · The paper itself

Abstract

BACKGROUND AND

objectiveInhalational exposures are a known cause of interstitial lung disease (ILD), but little is understood about their prevalence across ILD subtypes and their relationship with pulmonary function and survival.

methodsPatients with fibrotic ILD were identified from the multicentre Canadian Registry for Pulmonary Fibrosis. Patients completed questionnaires regarding ILD-related occupational and environmental exposures. The relationship between exposures and the outcomes of baseline age, gender, family history, pulmonary function and survival was analysed using linear and logistic regression models, linear mixed-effect regression models and survival analysis using multivariable Cox proportional hazards along with the log-rank test.

resultsThere were 3820 patients included in this study, with 2385 (62%) having ILD-related inhalational exposure. Exposed patients were younger, particularly in the idiopathic pulmonary fibrosis subgroup. Inhalational exposure was associated with male gender (adjusted OR 1.46, 95% CI 1.28-1.68, p < 0.001) and family history of pulmonary fibrosis (adjusted OR 1.73, 95% CI 1.40-2.15, p < 0.001). Patients with any inhalational exposure had improved transplant-free survival (hazard ratio 0.81, 95% CI 0.71-0.92, p = 0.001); this effect persisted across diagnostic subtypes. The relationship between exposures and annual change in forced vital capacity varied by ILD subtype.

conclusionPatients with fibrotic ILD report high prevalence of inhalational exposures across ILD subtypes. These exposures were associated with younger age at diagnosis, male gender and family history of pulmonary fibrosis. Identification of an inhalational exposure was associated with a survival benefit. These findings suggest that inhaled exposures may impact clinical outcomes in patients with ILD, and future work should characterize the mechanisms underlying these relationships.

Indexed as

Idiopathic Pulmonary FibrosisLung Diseases, InterstitialCanadaFibrosisHumansLungMaleRegistriesCanadian Registry for Pulmonary FibrosisCARE-PFfibrotic interstitial lung diseaseinhalational exposureoccupational exposure

Identifiers

PMID35512793
PMCPMC9296585
OpenAlexW4229002017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.